Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PV-001-DV and PV-001-DC Combination in Advanced Melanoma
NCT03990493Phase 1Unknown
- Sponsor
- PrimeVax Immuno-Oncology
- Start
- Apr 2024
- Primary completion
- Sep 2024
- Modality
- Whole Cell Cancer Vaccines, Oncolytic Viruses, Dendritic Cell Vaccines
01
Overview
Phase 1, open-label, single-arm trial of PV-001-DV and Autologous monocyte-derived lysate-pulsed dendritic cell vaccine PV-001-DC in melanoma, sponsored by PrimeVax Immuno-Oncology. Primary endpoint: Incidence and severity of Treatment-Emergent Adverse Events at 365 days. Status: unknown.
02
Drugs
PV-001-DVAutologous monocyte-derived lysate-pulsed dendritic cell vaccine PV-001-DC
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03990493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03990493.